{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:35Z","timestamp":1792787315306,"version":"4.5.0"},"reference-count":51,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canada Foundation for Innovation","award":["CFI; Project #: 45189"],"award-info":[{"award-number":["CFI; Project #: 45189"]}],"id":[{"id":"https:\/\/ror.org\/000az4664","id-type":"ROR","asserted-by":"crossref"}]},{"name":"McCaig Institute for Bone and Joint Health","award":["SPARC Ignite grant"],"award-info":[{"award-number":["SPARC Ignite grant"]}]},{"name":"Cal Wenzel Family Foundation Start-up Award","award":["2024_Black Scholar"],"award-info":[{"award-number":["2024_Black Scholar"]}],"id":[{"id":"https:\/\/ror.org\/05et1ec29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Science and Engineering Research Council grant","award":["NSERC; RGPIN-2024-06321"],"award-info":[{"award-number":["NSERC; RGPIN-2024-06321"]}],"id":[{"id":"https:\/\/ror.org\/00zgdb249","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,6,6]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist. Clinical trials in SLE have not consistently demonstrated an increased risk of thrombotic events and the effects of JAK inhibition on platelet function remain incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate whether the JAK1 inhibitor upadacitinib modulates platelet procoagulant membrane dynamics (PMD) in vitro and to explore the associated cytokine signatures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Whole blood from patients with SLE (n=10) and healthy controls (n=10) was preincubated with upadacitinib (0, 60 and 300\u2009ng\/mL). Platelet-rich plasma was analysed using confocal microscopy and Volocity software (Quorum Technology) to quantify PMD markers. We used Alexa Fluor 488 CD62p to detect degranulation, Alexa Fluor 568 Annexin-V to detect phosphatidylserine exposure and Alexa Fluor 647 PAC-1 to detect integrin \u03b1IIb\u03b23 activation. Participants were stratified as JAKi-activated or JAKi-null depending on whether PMD markers were amplified on JAK inhibition or remained unaffected. We then used Luminex xMAP technology to quantify 96 human plasma cytokines, chemokines and growth factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Platelet responses were heterogeneous. Approximately 30% of both groups exhibited increased platelet activation and procoagulant responses (\u2018JAKi-activated\u2019), whereas the remainder remained unaffected. Platelets of patients with SLE demonstrated elevated baseline activation, characterised as preactivation or autoactivation. JAKi-activated phenotypes were associated with increased plasma levels of interleukin (IL)-4 and tumour necrosis factor-beta (TNF-\u03b2) after JAK inhibition. In vitro, we showed that recombinant IL-4 and TNF-\u03b2 directly activated platelets or primed platelet responses to procoagulant agonists, supporting a potential indirect mechanism for the enhanced procoagulation observed in our JAKi-activated subpopulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib was associated with enhanced platelet activation and procoagulant responses in vitro in a subset of individuals with SLE and healthy controls. These findings are preliminary and hypothesis-generating. Further studies are required to determine clinical relevance and validate stratification approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-001983","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:17:22Z","timestamp":1783423042000},"page":"e001983","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study"],"prefix":"10.1136","volume":"13","author":[{"given":"Veronica","family":"Tsegai","sequence":"first","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5780-7542","authenticated-orcid":false,"given":"Halimat","family":"Lawal","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-6176","authenticated-orcid":false,"given":"Cini","family":"John","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibukun","family":"Akinrinade","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Duncan","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Dufour","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E H","family":"Barber","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Hazlewood","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-2737","authenticated-orcid":false,"given":"May Y","family":"Choi","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9115","authenticated-orcid":false,"given":"Ejaife O","family":"Agbani","sequence":"additional","affiliation":[{"name":"McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026092908101679000_13.2.e001983.1","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026092908101679000_13.2.e001983.2","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2026092908101679000_13.2.e001983.3","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026092908101679000_13.2.e001983.4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7573\/dic.2020-7-5","article-title":"Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients","volume":"9","author":"Pavelka","year":"2020","journal-title":"Drugs Context"},{"key":"2026092908101679000_13.2.e001983.5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026092908101679000_13.2.e001983.6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026092908101679000_13.2.e001983.7","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092908101679000_13.2.e001983.8","unstructured":"US Food and Drug Administration . FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021."},{"key":"2026092908101679000_13.2.e001983.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026092908101679000_13.2.e001983.10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122"},{"key":"2026092908101679000_13.2.e001983.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D"},{"key":"2026092908101679000_13.2.e001983.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127991","article-title":"Prothrombotic state, platelet activation and netosis in systemic lupus erythematosus","volume":"134","author":"Monz\u00f3n Manzano","year":"2019","journal-title":"Blood"},{"key":"2026092908101679000_13.2.e001983.13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kex216","article-title":"Comment on: Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus: reply","volume":"56","author":"Lood","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026092908101679000_13.2.e001983.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.20622"},{"key":"2026092908101679000_13.2.e001983.15","doi-asserted-by":"crossref","DOI":"10.1186\/ar2878","article-title":"Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study","volume":"11","author":"Gustafsson","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2026092908101679000_13.2.e001983.16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001183","article-title":"Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER registry","volume":"94","author":"Fern\u00e1ndez-Nebro","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2026092908101679000_13.2.e001983.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem002"},{"key":"2026092908101679000_13.2.e001983.18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1160\/TH04-06-0382","article-title":"Antiprothrombin antibodies detected in two different assay systems","volume":"93","author":"Bertolaccini","year":"2005","journal-title":"Thromb Haemost"},{"key":"#cr-split#-2026092908101679000_13.2.e001983.19.1","doi-asserted-by":"crossref","unstructured":"Canti V , Ramirez G , Bozzolo E , et al . PS4:70 Anti-phosphatidylserine\/prothrombin antibodies and cardiovascular risk in a SLE cohort of patients. 11th European Lupus Meeting, D\u00fcsseldorf, Germany, 21-24 March 2018. Abstract presentations","DOI":"10.1136\/lupus-2018-abstract.116"},{"key":"#cr-split#-2026092908101679000_13.2.e001983.19.2","doi-asserted-by":"crossref","unstructured":"March 2018:A69-A. doi:10.1136\/lupus-2018-abstract.116","DOI":"10.1136\/lupus-2018-abstract.116"},{"key":"2026092908101679000_13.2.e001983.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes388"},{"key":"2026092908101679000_13.2.e001983.21","article-title":"Risk of venous thromboembolism with Janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026092908101679000_13.2.e001983.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005742","article-title":"Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study","volume":"11","author":"Merrill","year":"2025","journal-title":"RMD Open"},{"key":"2026092908101679000_13.2.e001983.23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.thromres.2014.03.042","article-title":"Role of a Janus kinase 2-dependent signaling pathway in platelet activation","volume":"133","author":"Lu","year":"2014","journal-title":"Thromb Res"},{"key":"2026092908101679000_13.2.e001983.24","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.347"},{"key":"2026092908101679000_13.2.e001983.25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/psp4.12419","article-title":"Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach","volume":"8","author":"Koride","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026092908101679000_13.2.e001983.26","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080850"},{"key":"2026092908101679000_13.2.e001983.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab447"},{"key":"2026092908101679000_13.2.e001983.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2026092908101679000_13.2.e001983.29","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026092908101679000_13.2.e001983.30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","article-title":"Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis","volume":"55","author":"Mohamed","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2026092908101679000_13.2.e001983.31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0037-1613311","article-title":"Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF)","volume":"88","author":"Pintucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"2026092908101679000_13.2.e001983.32","doi-asserted-by":"publisher","DOI":"10.1159\/000237097"},{"key":"2026092908101679000_13.2.e001983.33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2001.00340.x"},{"key":"2026092908101679000_13.2.e001983.34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314744"},{"key":"2026092908101679000_13.2.e001983.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2026092908101679000_13.2.e001983.36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtha.2023.01.006","article-title":"Repeated platelet activation and the potential of previously activated platelets to contribute to thrombus formation","volume":"21","author":"De Simone","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2026092908101679000_13.2.e001983.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100075","article-title":"Preeclampsia: platelet procoagulant membrane dynamics and critical biomarkers","volume":"7","author":"Agbani","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026092908101679000_13.2.e001983.38","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jtha.2023.03.014","article-title":"Overexpression of facilitative glucose transporter-3 and membrane procoagulation in maternal platelets of preeclamptic pregnancy","volume":"21","author":"Agbani","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2026092908101679000_13.2.e001983.39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237115","article-title":"Hypercoagulability and inflammatory markers in a case of congenital thrombotic thrombocytopenic purpura complicated by fetal demise","volume":"11","author":"Skeith","year":"2022","journal-title":"J Clin Med"},{"key":"2026092908101679000_13.2.e001983.40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/a-1683-8455","article-title":"Activated platelets harbor SARS-CoV-2 during severe COVID-19","volume":"122","author":"Agbani","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026092908101679000_13.2.e001983.41","doi-asserted-by":"crossref","unstructured":"Agbani EO . A state-of-the-art talk: preeclampsia and platelet procoagulant membrane dynamics in. In: The International Society on Thrombosis and Haemostasis (ISTH). London, England, U.K: ISTH, 2022.","DOI":"10.1016\/j.rpth.2023.100075"},{"key":"2026092908101679000_13.2.e001983.42","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V90.7.2615","article-title":"Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses","volume":"90","author":"Heemskerk","year":"1997","journal-title":"Blood"},{"key":"2026092908101679000_13.2.e001983.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-787259"},{"key":"2026092908101679000_13.2.e001983.44","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-021-01051-5","article-title":"An update on antiphospholipid syndrome","volume":"23","author":"Xourgia","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2026092908101679000_13.2.e001983.45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2018.38","article-title":"The non-haemostatic role of platelets in systemic lupus erythematosus","volume":"14","author":"Linge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026092908101679000_13.2.e001983.46","first-page":"1190","article-title":"Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant?","volume":"27","author":"Ames","year":"2000","journal-title":"J Rheumatol"},{"key":"2026092908101679000_13.2.e001983.47","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000526"},{"key":"2026092908101679000_13.2.e001983.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024901"},{"key":"2026092908101679000_13.2.e001983.49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tracli.2012.02.004","article-title":"Platelets and cytokines: how and why?","volume":"19","author":"Garraud","year":"2012","journal-title":"Transfus Clin Biol"},{"key":"2026092908101679000_13.2.e001983.50","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12084"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-001983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:14:40Z","timestamp":1790694880000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/lupus-2026-001983"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-001983","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}